{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-267563","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2026-06-11T20:15:15+00:00","discovered_at":"2026-06-11T20:16:02.345280+00:00","generated_at":"2026-06-11T20:26:49.124861+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"All four proposals approved at Cardiff Oncology 2026 annual meeting, including equity plan increase to 15.15M shares","bullets":["All six director nominees elected; broker non-votes of ~22.3M shares for each.","Ratification of BDO USA as independent auditor for FY2026: 40.24M for, 1.07M against.","Amendment to 2021 Equity Incentive Plan increasing authorized shares to 15.15M approved: 10.74M for, 8.06M against.","Advisory say-on-pay vote on named executive officer compensation approved: 17.12M for, 1.77M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-267563","json":"https://secwatch.observer/filing/0001193125-26-267563.json","markdown":"https://secwatch.observer/filing/0001193125-26-267563.md","text":"https://secwatch.observer/filing/0001193125-26-267563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526267563/0001193125-26-267563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526267563/crdf-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:26:49.124861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0599419c01f039cd04aae32ba5f1e4d510485989","claim":"Cardiff Oncology, Inc. shareholders approved Election of six nominees for director at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 1 . All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. The result of the votes to elect the six (6) directors was as follows: Directors For Against Abstain Broker Non Vote Dr. James O. Armitage 18,806,657 0 522,756 22,285,435 Dr. Rodney Markin 18,647,050 0 682,361 22,285,437 Mani Mohindru, Ph.D. 18,942,979 0 386,435 22,285,434 Gary W. Pace, Ph.D. 18,877,743 0 451,668 22,285,437 Renee P. Tannenbaum, Pharm.D. 18,790,068 0 539,345 22,285,435 Lâle White 18,710,040 0 619,373 22,285,435","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526267563/0001193125-26-267563-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"653b7bb76b058d965b5fbffe1718936f7ad1cf1a","claim":"Cardiff Oncology, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 4. The advisory vote on the compensation of the Company's named executive officers was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 17,120,176 1,772,185 437,049 22,285,438","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526267563/0001193125-26-267563-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"78860f8e475838418d16f87a0d54ab05dfa8969f","claim":"Cardiff Oncology, Inc. shareholders approved Amendment to 2021 Equity Incentive Plan to increase number of shares issuable to 15,150,000 shares at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 3. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 15,150,000 shares was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 10,740,460 8,063,520 525,431 22,285,437","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526267563/0001193125-26-267563-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"b3f724f63ffd87a271a4e69e01a4a63eedd5b19b","claim":"Cardiff Oncology, Inc. shareholders approved Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year 2026 at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 2. The appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 40,239,508 1,070,807 304,529 4","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526267563/0001193125-26-267563-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}